A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge

• Drug: Placebo
  
  A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
• Drug: Allegra
  
  A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
• Drug: Allegra-D
  
  A single oral dose of Allegra-D is dosed to subjects as an active comparator.
• Drug: PF-03654746
  
  A single oral dose of PF-03654746 is the investigational drug being studied.

• Placebo Comparator: Placebo
  
  Intervention: Drug: Placebo
• Active Comparator: Allegra
  
  Intervention: Drug: Allegra
• Active Comparator: Allegra-D
  
  Intervention: Drug: Allegra-D
• Experimental: PF-03654746
  
  Intervention: Drug: PF-03654746

Inclusion Criteria:

• Male or female subjects 19-55 years with allergic rhinitis requiring treatment within the previous 2 years.
• Subjects that respond to a ragweed nasal allergen challenge at screening.

Exclusion Criteria:

• History of asthma or FEV1 < 80% predicted.
• Significant concomitant disease or medications.
• Symptoms of allergic rhinitis within 2 weeks prior to screening.